Endpoints NewsOriginal article
Otsuka succeeds with kidney drug; BioNTech downgrades revenue projection
Phase 3positiveVoyxactPositive
AI Analysis
Summary
Otsuka's Voyxact met a key secondary endpoint in the Phase 3 VISIONARY study for IgA nephropathy. BioNTech downgraded its revenue projection.
Clinical Trial Data
Phase
Phase 3
Financial Highlights
Guidance
BioNTech downgraded revenue projection
Outcome Details
Met key secondary endpoint in Phase 3 VISIONARY study
Importance:7/10
Sentiment:
0.60
Phase 3 datakidney diseasesecondary endpointrevenue guidance downgrade
Read the original article
Published by Endpoints News on August 4, 2026 2:50 PM